 |
|
|
|||||
Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both 'Buy' and 'Sell' ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:
Category:
News and Media
In the week ending September 27, the Sensex experienced a weekly gain of about 1.2%, while the smallcap index remained largely unchanged. However, 8 smallcap stocks achieved significant weekly price increases between 15% and 37%. (Data Source: ACE Equity)
Category:
News and Media
Vinit Bolinjkar of Ventura Securities highlights Maruti and Adani Green as top picks. Maruti aims to establish 25,000 charging points by FY25. Adani Green is also promising with upcoming IPOs. Banking, IT, and metal sectors are expected to continue performing well, although some profit-taking may occur in the coming weeks.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||